Sean Harper left his role as head of Amgen, Inc. research and development two years ago to get involved in forming new biopharma companies with former Amgen colleague and venture capital veteran Beth Seidenberg – and the pair already have raised their second and third VC funds. They announced the two new funds totaling $500m on 15 December and the launch of new immunology-focused drug developer Acelyrin Inc., helmed by former Amgen scientist and AbbVie Inc. R&D executive Shao-Lee Lin.
Westlake Village BioPartners Closes Two VC Funds Totaling $500m
Sean Harper/Beth Seidenberg-Helmed Firm Also Launches Acelyrin
A $70m fund will back prior investments, while a $430m fund will launch new biotech firms. Harper and Seidenberg tapped into their Amgen connections for the CEO who helms new company Acelyrin.
More from Financing
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
The four-year-old firm said it plans to advance programs toward the clinic from the funding round, which comes just over a year after signing two major pharma partnerships.
• By
Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.
• By
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.
More from Business
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.